Potent Synergistic Anti-Human Immunodeficiency Virus (HIV) Effects Using Combinations of the CCR5 Inhibitor Aplaviroc with Other Anti-HIV Drugs

Aplaviroc (AVC), an experimental CCR5 inhibitor, potently blocks in vitro the infection of R5-tropic human immunodeficiency virus type 1 (R5-HIV-1) at subnanomolar 50% inhibitory concentrations. Although maraviroc is presently clinically available, further studies are required to determine the role...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Nakata, Hirotomo, Steinberg, Seth M., Koh, Yasuhiro, Maeda, Kenji, Takaoka, Yoshikazu, Tamamura, Hirokazu, Fujii, Nobutaka, Mitsuya, Hiroaki
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Microbiology (ASM) 2008
Gaiak:
Antiviral Agents
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2415794/
https://ncbi.nlm.nih.gov/pubmed/18378711
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01299-07
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak